Instil Bio, Inc. (TIL) Dividend History

Company News

• Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025

  Instil Bio and ImmuneOnco announced the progress of their Phase 2 trial of AXN-2510/IMM2510, a PD-L1xVEGF bispecific antibody, in combination with chemotherapy for first-line NSCLC in China. The trial is expected to complete enrollment in Q3 2025, with initial results anticipated in 2H 2025.

  GlobeNewswire Inc.
• Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

  Instil Bio reported its Q1 2025 financial results, including ongoing enrollment of 1L NSCLC patients in a China trial of AXN-2510/IMM2510 in combination with chemotherapy, with initial data expected in 2H 2025. The company also plans to initiate a U.S. clinical study of the same combination in 1L NSCLC before the end of 2025.

  GlobeNewswire Inc.
• Tumor-infiltrating Lymphocyte (TIL) Therapies Global Market Report 2025: 75+ Therapies are Under Development and 100+ Clinical Trials are Underway Globally

  The TIL Therapies Market is projected to grow from USD 87 million in 2024 to USD 5 billion by 2035, at a CAGR of 40%. Over 75 therapies are under development and more than 100 clinical trials are underway globally, with key players including Iovance Biotherapeutics, Bristol-Myers Squibb, and Instil Bio.

  GlobeNewswire Inc.

  Featured Companies: BMY IOVA
• Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody

  Instil Bio's collaborator, ImmuneOnco, has dosed the first patient in a phase 1b/2 clinical trial of IMM2510/SYN-2510 in combination with chemotherapy for advanced NSCLC in China. Instil plans to initiate a potential first-line advanced NSCLC clinical trial of IMM2510/SYN-2510 combined with chemotherapy in the second half of 2025.

  GlobeNewswire Inc.
• Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising?

  Summit Therapeutics' stock price has soared over 600% since the end of 2023 due to positive trial results for its cancer therapy ivonescimab, which could potentially unseat Merck's Keytruda as the top-selling cancer treatment. However, the company is still pre-commercial and its market valuation may be too high at the moment.

  The Motley Fool

  Featured Companies: MRK SMMT